New immune cell therapy tracks itself in the body to fight lymphoma
NCT ID NCT07343934
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new type of cell therapy for people with follicular lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to target cancer cells and also carry a tracking tag that can be seen on PET scans. Only 6 participants will be enrolled to check safety and whether the tracking method works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified immune cells (huCART19-IL18-eDHFR)
- What this could lead to
- If it works, this could point toward a new treatment option for people with follicular lymphoma that has stopped responding to standard therapies.
- What could go wrong
- This is a very early phase 1 trial with only 6 participants, so it is too small to prove effectiveness. The main goal is safety and imaging, not treatment benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.